



Eleven Biotherapeutics  
Investor Relations Department  
245 First Street, Suite 1800  
Cambridge, MA 02142  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

#### NASDAQ: EBIO

Last Trade:	1.57
Trade Time:	4:00 PM ET July 24, 2017
Change:	0.06 <span style="color: green;">↑</span> (3.974%)
Day Range	1.50 - 1.57
52-Week Range	1.31 - 5.97
Volume	73,754

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Eleven Biotherapeutics, Inc. is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on our Targeted Protein Therapeutics (TPTs) platform. Our TPTs genetically combine targeting antibody fragments with cytotoxic protein payloads to create a single fusion protein through Eleven's proprietary one-step manufacturing process.

We have designed TPTs with the potential to offer:

- Multiple advantages in treating cancer over traditional antibody drug conjugates.
- Effective tumor targeting with cancer cell-killing... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

June 12, 2017

[Eleven Biotherapeutics to Present at 2017 Marcum MicroCap Conference](#)

June 6, 2017

[Eleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of Vicinium™ in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer](#)

June 1, 2017

[Eleven Biotherapeutics Announces Data and Safety Monitoring Board \(DSMB\) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder Cancer Based on Review of Safety and Efficacy Data](#)

May 17, 2017

[Eleven Biotherapeutics Continues Expansion of Clinical Development Team with Appointment of David Brooks, M.D., Ph.D., to Senior Vice President, Clinical Development](#)

May 4, 2017

[Eleven Biotherapeutics Reports First Quarter 2017 Financial Results](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

March 24, 2017

[Annual Report \(10-K\)](#)

April 7, 2017

[Proxy Statement \(DEF 14A\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

November 14, 2016

[Quarterly Report \(10-Q\)](#)

August 12, 2016

[Quarterly Report \(10-Q\)](#)